Stocks in Action USA: Adaptive Biotechnologies, Trupanion and Duolingo.
Reading Time: 4 minutes
Adaptive Biotechnologies (ADPT): The biotech starts off strong into the year – MRD business is growing rapidly! Adaptive Biotechnologies has made a convincing start in the first quarter of 2025. The biotech company specializing in immuno-based diagnostics was able to increase its revenue by 25% compared to the previous year, reaching $52.4 million – significantly driven by the booming minimal residual disease (MRD) business. In particular, the clonoSEQ tests for monitoring cancer relapses surged: The number of tests increased by 36% to...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
